GlassScriptPhysician profile
John B Clendenin
NPI 1265412563
$10,262.35
in general payments reported to CMS, 2019-2025
34 companies · $1,557 in 2025
The $1,557 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,699 · 2020: $827 · 2021: $1,470 · 2022: $1,382 · 2023: $1,862 · 2024: $1,465 · 2025: $1,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,839 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,839.42 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,473.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,182.84 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $918.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $813.29 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $746.40 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.29 | 2019-2025 | Jardiance |
| Pfizer INC. | $586.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $536.41 | 2019-2022 | |
| Abbvie INC. | $364.98 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Merck Sharp & Dohme LLC | $241.55 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $208.23 | 2023-2025 | Rexulti |
| Abbott Laboratories | $203.20 | 2022-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $141.14 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $123.29 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $113.31 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $104.63 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $95.57 | 2020-2025 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $65.66 | 2019-2020 | |
| Sanofi Pasteur INC. | $63.21 | 2019 | |
| Exact Sciences Corporation | $62.37 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $59.97 | 2021 | |
| Idorsia Pharmaceuticals US INC | $57.56 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $51.64 | 2020-2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.13 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $42.72 | 2022 | |
| Esperion Therapeutics, INC. | $41.62 | 2025 | Nexletol |
| Astellas Pharma US INC | $34.57 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $28.54 | 2025 | Gemtesa |
| Shire North American Group INC | $21.93 | 2019 | |
| Medtronic, INC. | $21.28 | 2025 | Interstim |
| Amarin Pharma, INC. | $19.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.86 | 2021 | |
| Celgene Corporation | $12.80 | 2019 | |
| Axsome Therapeutics, INC. | $12.06 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clendenin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.